Laddar populära aktier...
Q1: 33% y-o-y ARR growth and 15% adj. EBITDA margin All FY'24 guidance items upgraded once again Con...
Wood M&A lifts '24e-'26e EPS by 4-6%, EBITA up 12-17% Share now trading at 9.
Consti reports its Q1/24 results on 25th of April. We expect continued sales decline during the seas...
Redeye leaves an initial comment following the Q1 report published by Magle this morning.
Continued weakenss in Genetics holding back sales growth Good growth in Consumables and Technology E...
Hansa’s Q1 result includes a positive outlook in 2024 supported by additional countries and the Euro...
We lower '24e-'26e adj. EBITA by 10-3%... ...on continued weakness in macro data '24e EV/EBITA of ~8...
Today, Evaxion reported the full EVX-01 dosing of the first patient in the phase II study of EVX-01.
Q1e sales SEK 33.2m, up 25% y-o-y, EBIT margin 33.8% (24.
Redeye briefly comments on Circio’s rights issue. We pause our coverage.
Q1 report due 7 May Q1'24e net sales SEK 206m, EBITA SEK 30m We reiterate our fair value range of SE...
Raute reports Q1 results on May 3. We estimate earnings to improve over the course of the year, driv...
Redeye comments on Medrave's new contract with VGR.
Fiskars' main markets have likely remained subdued during Q1.
Ny styrelse inför split GIG har tagit ytterligare ett steg inför den stundande spliten och utsett en...